DOS-APSGP-FY22-001: U.S. Ambassador’s President’s Emergency Plan for AIDS Relief (PEPFAR) Small Grants Program Financial Year (FY) 2022
Closed
This grant is closed. A newer notice from the same program is open now: Advancing Global Health (DFOP0017890). Status: Closes February 14, 2027 (99 days left). It is in our archive of U.S. Mission to Malawi notices from 2022.
U.S. Mission to Malawi offered grants of up to $10,000 (at least $3,000) to nonprofits. It expected to make about 10 awards worth $100,000 in total. Applications closed on May 31, 2022.
From the official notice on Grants.gov, last changed March 31, 2022. Checked November 7, 2026.
- Award ceiling$10,000
- Award floor$3,000
- Total funding$100,000
- Expected awards10
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | April 1, 2022 |
|---|---|
| Deadline | May 31, 2022 |
| Archived by Grants.gov | June 30, 2022 |
Who can apply
This opportunity was open to nonprofits.
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
1. Community and Faith Based Organizations2. Youth Networks3. Non-profit organizations4. Key Population Networks and Organizations
Is this a realistic fit?
- Past The U.S. President's Emergency Plan for AIDS Relief Programs awards averaged $146,897; this notice allows up to $10,000 per award.
- Most of the program's money (74% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
PEPFAR is recognized widely for efficiently and effectively investing U.S. taxpayer dollars to save millions of lives and change the course of the HIV pandemic. Through implementation of PEPFAR strategies and the use of data, PEPFAR constantly innovates to generate greater efficiencies, drive down costs, and increase impact. PEPFAR is a key partner and investor in the Malawi’s national response to combat HIV and AIDS. As part of this national response, the PSGP seeks to support projects that will work directly with communities to promote HIV/AIDS prevention, testing, treatment, and adherence practices. In 2022 PSGP focuses specifically on: promotion of health seeking behaviors and encouragement of back to care efforts; dissemination of accurate and authentic HIV public messages; solutions to stigma and discrimination; treatment literacy; and enhancing HIV prevention, care, and support. In 2021-2022, the U.S. Embassy supported six organizations across Malawi to implement projects that: strengthened linkages to health facilities for equitable access to HIV prevention, treatment and care services; promoted treatment adherence for people living with HIV; provided job skills training for women and girls living with HIV; and involved press to effectively cover HIV/AIDS issues. Program Objectives: Ensure Malawians, regardless of age and sex, are reached with appropriate messaging on testing, antiretroviral treatment, and those living with HIV/AIDS are virally suppressed. Expected Results Specific results could include the following: • Promoting heath seeking behaviors, increase demand for HIV services and mitigate barriers that contribute to treatment interruption. • Providing solutions to stigma and discrimination among people living with HIV and key populations. • Increasing treatment literacy. • Enhance HIV prevention, care, and support. Main Activities To achieve the goals and expected results, the program could include the following: • Support accurate and authentic public messages on HIV to address misinformation and increase treatment literacy. • Enhance community systems for the prevention of Sexual and Gender Based Violence (SGBV) and stigma discrimination against victims of SGBV. • Eliminate cultural and legal barriers that prevent equal access to health services. • Promote HIV prevention and encourage healthy living among HIV positive recipients of care by encouraging adherence, retention, and back to care efforts.
Who has won The U.S. President's Emergency Plan for AIDS Relief Programs grants before
From fiscal 2021 to 2025, The U.S. President's Emergency Plan for AIDS Relief Programs (19.029) awarded $117 million across 794 grant awards, an average of $146,897 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 1 | $89.9 million |
| Miscellaneous Foreign Awardees | 321 | $7.9 million | |
| Ho Chi Minh City HIV/AIDS Association | 4 | $673,404 | |
| Tamra for Social Development Organization (TDS) | 3 | $638,998 | |
| National Empowerment Network of People Living with HIV / AIDS (Nephak) | 3 | $513,403 |
Applying now
This notice no longer takes applications. Apply under the newer notice, DFOP0017890, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is DOS-APSGP-FY22-001 still open?
No. It closed on May 31, 2022. A newer notice is open: DFOP0017890, closes February 14, 2027 (99 days left).
Who can apply for U.S. Ambassador’s President’s Emergency Plan for AIDS Relief (PEPFAR) Small Grants Program Financial Year (FY) 2022?
U.S. Mission to Malawi accepted applications from nonprofits. The notice adds further conditions, so read its eligibility section.
What is the deadline for U.S. Ambassador’s President’s Emergency Plan for AIDS Relief (PEPFAR) Small Grants Program Financial Year (FY) 2022?
Closed May 31, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $10,000 each. About $100,000 in total across about 10 awards.
Who has won The U.S. President's Emergency Plan for AIDS Relief Programs grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Miscellaneous Foreign Awardees, Ho Chi Minh City HIV/AIDS Association. The program made 794 awards worth $117 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)